Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    Arlanda is your partner for the Brazil market.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    Hypericin

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HyBryte Results Debut at 2026 US Cutaneous Lymphoma Workshop
    HyBryte Results Debut at 2026 US Cutaneous Lymphoma Workshop

    23 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/hybryte-treatment-results-to-be-presented-at-us-cutaneous-lymphoma-consortium-annual-workshop-2026-302721423.html

    PR NEWSWIRE
    23 Mar 2026
    Share Share
    Soligenix Announces HyBryte Clinical Summary Published
    Soligenix Announces HyBryte Clinical Summary Published

    19 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-hybryte-clinical-summary-published-in-expert-opinion-on-investigational-drugs-302718249.html

    PR NEWSWIRE
    19 Mar 2026
    Share Share
    Soligenix Announces Top-line Results of the Ph 2a Study of SGX302
    Soligenix Announces Top-line Results of the Ph 2a Study of SGX302

    17 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-announces-top-line-results-of-the-phase-2a-study-of-sgx302-synthetic-hypericin-in-patients-with-mild-to-moderate-psoriasis-302644314.html

    PR NEWSWIRE
    17 Dec 2025
    Share Share
    Soligenix Reaches Enrollment Milestone In Phase 3 Trial
    Soligenix Reaches Enrollment Milestone In Phase 3 Trial

    19 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-achieves-enrollment-milestone-for-planned-interim-analysis-in-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-302619926.html

    PR NEWSWIRE
    19 Nov 2025
    Share Share
    Soligenix Refreshes US Medical Advisory Board For Lymphoma
    Soligenix Refreshes US Medical Advisory Board For Lymphoma

    14 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-updates-united-states-medical-advisory-board-for-cutaneous-t-cell-lymphoma-302582841.html

    PR NEWSWIRE
    14 Oct 2025
    Share Share
    Soligenix Reaches Safety Milestone In Phase 3 Trial Of Hybryte™
    Soligenix Reaches Safety Milestone In Phase 3 Trial Of Hybryte™

    07 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/soligenix-achieves-important-safety-milestone-in-its-confirmatory-phase-3-clinical-trial-of-hybryte-for-the-treatment-of-cutaneous-t-cell-lymphoma-302576600.html

    PR NEWSWIRE
    07 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.